Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated tanespimycin (17-N-Allylamino-17-Demethoxygeldanamycin) in patients with systemic mastocytosis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Mastocytosis

Drugs mentioned

• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Status: COMPLETED